GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
A large retrospective study indicates that patients with inflammatory bowel disease (IBD) who use GLP-1 receptor agonists have a significantly lower risk of developing colorectal cancer. The findings suggest a potential protective benefit for high-risk populations, including those with comorbid type 2 diabetes.
Why it matters
This research could influence clinical treatment guidelines for IBD patients, offering a new therapeutic strategy to mitigate long-term cancer risks.
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting, taking place June 25 to June 27 in Singapore.
The article reports on medical research findings without editorializing or taking a political stance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in